Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib + temozolomide with concurrent radiotherapy in postoperative high-grade glioma
ChiCTR2100052129Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of donafenib in glioma, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Progression-free survival and Adverse events. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
donafenib
03
Conditions
glioma
Beyond the preview
Go deeper on ChiCTR2100052129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100052129.